PURPOSE: To determine if physician prediction of survival duration (PSD) is accurate for patients with metastatic breast or prostate cancer. METHODS: Radiation Therapy Oncology Group 9714 (RTOG 9714) was a randomized comparison of radiotherapy schedules for treatment of bone metastases. The treating physician assigned a baseline Karnofsky Performance Score (KPS) and predicted survival duration at study entry. Patients completed the Functional Assessment of Cancer Therapy (FACT). These three were compared to actual survival time. RESULTS:Eight hundred ninety-eight patients were eligible and analyzable. Actual median survival was 9.3 months. The median PSD was 12 months. PSD, KPS, and FACT were all moderately correlated with actual survival. Patients with higher KPS had a longer survival time (882 patients, Spearman's rho = 0.259, p < 0.0001). The median survival of the 618 expired patients is 6.5 months (PSD was 12 months). The PSD was within 1 month of actual survival in 61 (10%), with 177 (29%) patients surviving more than 1 month longer than predicted and 375 (61%) surviving more than 1 month less than predicted. A univariate analysis of actual overall survival was performed, dividing the PSD into 4 groups. For predicted survivals of 6 months or less, less than 6 to less than 12 months, 12 months, and more than 12 months, median actual survivals were 7.0, 7.2, 9.7. and 13.5 months (p < 0.0001). CONCLUSIONS:KPS, FACT scores, and PSD all are correlated with actual survival. Physicians on this study were able to predict which patients would have longer survival times, although prediction of survival was optimistic compared to actual survival by an average of 3 months.
RCT Entities:
PURPOSE: To determine if physician prediction of survival duration (PSD) is accurate for patients with metastatic breast or prostate cancer. METHODS: Radiation Therapy Oncology Group 9714 (RTOG 9714) was a randomized comparison of radiotherapy schedules for treatment of bone metastases. The treating physician assigned a baseline Karnofsky Performance Score (KPS) and predicted survival duration at study entry. Patients completed the Functional Assessment of Cancer Therapy (FACT). These three were compared to actual survival time. RESULTS: Eight hundred ninety-eight patients were eligible and analyzable. Actual median survival was 9.3 months. The median PSD was 12 months. PSD, KPS, and FACT were all moderately correlated with actual survival. Patients with higher KPS had a longer survival time (882 patients, Spearman's rho = 0.259, p < 0.0001). The median survival of the 618 expired patients is 6.5 months (PSD was 12 months). The PSD was within 1 month of actual survival in 61 (10%), with 177 (29%) patients surviving more than 1 month longer than predicted and 375 (61%) surviving more than 1 month less than predicted. A univariate analysis of actual overall survival was performed, dividing the PSD into 4 groups. For predicted survivals of 6 months or less, less than 6 to less than 12 months, 12 months, and more than 12 months, median actual survivals were 7.0, 7.2, 9.7. and 13.5 months (p < 0.0001). CONCLUSIONS: KPS, FACT scores, and PSD all are correlated with actual survival. Physicians on this study were able to predict which patients would have longer survival times, although prediction of survival was optimistic compared to actual survival by an average of 3 months.
Authors: B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Thomas A Buchholz; Ya-Chen Tina Shih Journal: J Oncol Pract Date: 2014-04-22 Impact factor: 3.840
Authors: Sara Mandelli; Emma Riva; Mauro Tettamanti; Ugo Lucca; Davide Lombardi; Gianmaria Miolo; Simon Spazzapan; Rita Marson Journal: Support Care Cancer Date: 2020-08-31 Impact factor: 3.603
Authors: Carsten Nieder; Kent Angelo; Astrid Dalhaug; Adam Pawinski; Ellinor Haukland; Jan Norum Journal: Oncol Lett Date: 2015-09-02 Impact factor: 2.967
Authors: Michala Skovlund Sørensen; Thomas Alexander Gerds; Klaus Hindsø; Michael Mørk Petersen Journal: Clin Orthop Relat Res Date: 2018-08 Impact factor: 4.176
Authors: Michael F Gensheimer; A Solomon Henry; Douglas J Wood; Trevor J Hastie; Sonya Aggarwal; Sara A Dudley; Pooja Pradhan; Imon Banerjee; Eunpi Cho; Kavitha Ramchandran; Erqi Pollom; Albert C Koong; Daniel L Rubin; Daniel T Chang Journal: J Natl Cancer Inst Date: 2019-06-01 Impact factor: 13.506
Authors: Michael F Gensheimer; Sonya Aggarwal; Kathryn R K Benson; Justin N Carter; A Solomon Henry; Douglas J Wood; Scott G Soltys; Steven Hancock; Erqi Pollom; Nigam H Shah; Daniel T Chang Journal: J Am Med Inform Assoc Date: 2021-06-12 Impact factor: 4.497
Authors: Miriam Vázquez; Manuel Altabas; Diana C Moreno; Abraham A Geng; Santiago Pérez-Hoyos; Jordi Giralt Journal: Front Oncol Date: 2021-04-23 Impact factor: 6.244
Authors: Jonathan Agner Forsberg; John Eberhardt; Patrick J Boland; Rikard Wedin; John H Healey Journal: PLoS One Date: 2011-05-13 Impact factor: 3.240